Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia

J Clin Lipidol. 2015 Jan-Feb;9(1):107-12. doi: 10.1016/j.jacl.2014.08.005. Epub 2014 Aug 23.

Abstract

We report the case of a 49-year-old woman with homozygous familial hypercholesterolemia and a complicated cardiovascular history, treated for 5 years with a microsomal triglyceride transfer protein inhibitor in addition to her other lipid-lowering therapy.

Keywords: CYP3A4 inhibitors; Cholesterol; Homozygous familial hypercholesterolemia; Liver function tests; Lomitapide; MTP inhibitor; Warfarin.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alanine Transaminase / blood
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / therapeutic use*
  • Anticoagulants / therapeutic use
  • Aspartate Aminotransferases / blood
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Blood Component Removal
  • Carrier Proteins / antagonists & inhibitors*
  • Carrier Proteins / metabolism
  • Cholesterol / blood
  • Female
  • Hematoma / diagnostic imaging
  • Hematoma / drug therapy
  • Hematoma / etiology
  • Humans
  • Hyperlipoproteinemia Type II / drug therapy*
  • Liver Function Tests
  • Magnetic Resonance Imaging
  • Middle Aged
  • Radiography

Substances

  • Anticholesteremic Agents
  • Anticoagulants
  • BMS201038
  • Benzimidazoles
  • Carrier Proteins
  • microsomal triglyceride transfer protein
  • Cholesterol
  • Aspartate Aminotransferases
  • Alanine Transaminase